Outcome of Board Meeting

GLAND PHARMA LIMITED GLAND November 06, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25th floor, Dalal Street Plot no. C-1, Block G, Bandra Kurla Complex Bandra Mumbai - 400 001 (East), Mumbai - 400 051 Scrip Code: 543245 Symbol: GLAND (ISIN: INE068V01023) Dear Sir/Madam, Sub: Outcome of the Board Meeting In continuation to our intimation dated October 21, 2026, regarding the Board Meeting Notice, we would like to inform you that the Board of Directors (the “Board”) of Gland Pharma Limited (the “Company”) at its Meeting held today, i.e. Friday, November 06, 2026, has inter-alia considered and approved the Unaudited Financial Results (standalone and consolidated) along with the Limited Review Report(s) for the quarter and half year ended September 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations’) which has been duly reviewed and recommended by the Audit Committee. In this regard, please find enclosed copies of the: 1. Unaudited Financial Results (standalone and consolidated) along with Limited Review Report(s) of the Company for the quarter and half year ended September 30, 2026 prepared in compliance with Indian Accounting Standards (Ind AS) 2. Press Release and Investor Presentation on the financial results of the Company for the above period. The Board Meeting commenced at 15.00 Hrs. IST and ended at 16.15 Hrs. IST. This is for your information and records. Yours truly, For Gland Pharma Limited Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer Encl: As above Regd. Office: Corporate Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads Plot No. 11 & 84, TSIIC Phase: IV D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Pashamylaram (V), Patancheru (M), Sangareddy District Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Hyderabad 502307, Telangana, India Tel: +91-40-30510999 Fax: +91 0-30510800 Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com Deloitte Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Haskins & Sells Bengaluru – 560 001 Karnataka, India Tel: +91 80 6188 6000 Fax: +91 80 6188 6011 INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Gland Pharma Limited (“the Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as “the Group”), for the quarter and half year ended September 30, 2026 (“the Statement”) being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”). 2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Holding Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4. The Statement includes the results of the following entities: Srl. Name of the entity Relationship 1 Gland Pharma Limited Holding Company 2 Gland Pharma International Pte. Ltd., Singapore Wholly-owned subsidiary Subsidiaries of Gland Pharma International Pte. Ltd.: 3 Gland Pharma USA Inc., USA 4 Phixen SAS, France Wholly-owned subsidiaries Subsidiaries of Phixen SAS: 5 Cenexi SAS, France 6 Cenexi HSC SAS, France 7 Cenexi Laboratories Thissen SA, Belgium Wholly-owned subsidiaries 8 Phineximmo SA, Belgium 9 Gland Pharma Europe SAS, France Page 1 of 2 D eloitte Haskins & Sells 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. We did not review the interim financial information of two subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total assets of 3,750.03 million as at September 30, 2026, total revenues of 1,194.22 million and 2,848.76 million for the quarter and half year ended September 30, 2026 respectively, total loss after tax of 333.37 million and 250.93 million for the quarter and half year ended September 30, 2026 respectively, total comprehensive loss of 333.37 million and 250.93 million for the quarter and half year ended September 30, 2025 respectively and net cash outflow of 20.23 million for the half-year ended September 30, 2026, as considered in the Statement. This interim financial information have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter. 7. The unaudited consolidated financial results includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of 36.59 million as at September 30, 2026, total revenue of Nil for the quarter and half year ended September 30, 2026, total loss after tax of 1.32 million and 3.10 million for the quarter and half year ended September 30, 2026, respectively and total comprehensive loss of 1.32 million and 3.10 million for the quarter and half year ended September 30, 2026, respectively and net cash outflow of 3.33 million for the half-year ended September 30, 2026, as considered in the Statement. According to the informatio [Showing first 8,000 characters — download PDF for full document]